Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

On Monday, Protalix BioTherapeutics, Inc. (NASDAQ:PLX) reported fiscal 2024 earnings of 4 cents, beating the consensus of 1 cent.

The company recorded 2024 sales of $53.40 million, up 31% year over year, slightly below the consensus of $53.94 million.

The increase resulted primarily from an increase of $11.8 million in sales to Chiesi, an increase of $0.6 million in sales to Brazil, and an increase of $0.1 million in sales to Pfizer.

Protalix is a biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins expressed through its plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration approval of a protein produced through plant cell-based in suspension expression system.

Also Read: Incyte’s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical ...